معرفی
Dr. Sharmistha Datta Gupta is affiliated with the School of Cardiovascular & Metabolic Health at the University of Glasgow. Her research focuses on cardiovascular therapeutics, particularly in heart failure management and clinical pharmacology. She contributed to a 2025 study examining sacubitril/valsartan's efficacy in heart failure patients with reduced ejection fraction, leveraging insights from the PARADIGM-HF trial.
Research Interests: Her work centers on optimizing drug therapies for heart failure, evaluating treatment interactions (e.g., beta-blockers), and advancing clinical trial methodologies in cardiovascular medicine. This study highlights her expertise in analyzing complex pharmacological interactions in high-risk cardiac populations.
Publications: Her 2025 article in European Journal of Heart Failure provides novel insights into combination therapies for heart failure, emphasizing real-world applicability of landmark clinical trials.